USP18 and chronic myelogenous leukemia, BCR-ABL1 positive: Reports have shown that USP18 is involved in chronic myeloid leukaemia and melanoma by regulating IFN-modulating signaling, indicating its role in cancer-associated immune responses [20, 21].